ASX · AVE.AX
Avecho Biotechnology Limited
A$0.01+A$0.00 (+7.69%)
Avecho Biotechnology Limited’s quoted price sits in the lower half of its reported 52-week range, 48.15% below the high.
Loading market information…
ASX · PAB.AX · AUD
Stock price, earnings
Quote as of Oct 29, 2026, 10:59 PM UTC. Cached market data; not a live quote.
One-year closing-price history · AUD. Historical prices are not a forecast.
Patrys Limited’s quoted price sits in the lower half of its reported 52-week range, 53.85% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Patrys Limited’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Based in Melbourne, Australia, Patrys Limited and its subsidiaries specialize in developing and commercializing advanced antibody technologies for cancer treatment. Their leading therapeutic, Deoxymab 3E10, is a distinctive DNA damage-repair antibody capable of penetrating cell nuclei. The company's pipeline also includes PAT-DX1, an antibody fragment specifically designed to target both primary and secondary brain cancers. Furthermore, Patrys is progressing PAT-DX3, a full-sized antibody that shares PAT-DX1's DNA-binding and DNA damage repair blocking properties, currently being evaluated for its tissue distribution and pharmacokinetic profile. Another promising development is PAT-DX1-NP, a product leveraging the targeted delivery of therapeutic payload-carrying nanoparticles directly into cancer cells. Patrys Limited was established in 2006.
Latest available per-share figures in AUD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 07:55 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
A$0.01+A$0.00 (+7.69%)
Avecho Biotechnology Limited’s quoted price sits in the lower half of its reported 52-week range, 48.15% below the high.
A$0.07A$0.00 (0.0%)
Nanollose Limited’s quoted price sits in the upper half of its reported 52-week range, 10.84% below the high.
A$0.02A$0.00 (0.0%)
Neurotech International Limited’s quoted price sits in the upper half of its reported 52-week range, 19.05% below the high.
A$0.35+A$0.02 (+4.55%)
ImExHS Limited’s quoted price sits in the lower half of its reported 52-week range, 26.6% below the high.
A$0.05A$0.00 (0.0%)
BTC Health Limited’s quoted price sits in the lower half of its reported 52-week range, 27.14% below the high.
A$0.02-A$0.00 (-4.76%)
Althea Group Holdings Limited’s quoted price sits in the lower half of its reported 52-week range, 44.44% below the high.
A$0.02A$0.00 (0.0%)
MedAdvisor Limited’s quoted price sits in the lower half of its reported 52-week range, 93.02% below the high.
A$0.04A$0.00 (0.0%)
Immuron Limited’s quoted price sits in the lower half of its reported 52-week range, 59.18% below the high.
